A new test can help doctors determine whether a woman experiencing hair loss is likely to benefit from antiandrogen therapies, Business Wire reports.
Irvine, Calif. - A new test can help doctors determine whether a woman experiencing hair loss is likely to benefit from antiandrogen therapies, Business Wire reports.
According to dermatology research and development company DermaGenoma, the HairDX Genetic Test for Female Androgen Sensitivity offers a new genetic screening for women suffering from or at risk of androgenetic alopecia (AGA). The test was unveiled to physicians at the International Society of Hair Restoration Surgery’s 18th Annual Scientific Meeting, held in Boston in October.
The test examines genetic and epigenetic variations in a woman’s androgen receptor gene, then assesses her androgen sensitivity to determine if her hair loss has an androgenic origin.
Patients with high androgen sensitivity could benefit from antiandrogen therapies. Understanding the origin of the hair loss will help physicians select the most effective treatment, the company says.